07 Jan 2001

Betnesol®-V Lotio (Betnesol®-V Lotio 0,1%) - Deutschland

Updated: 07 Jan 2001

Betnesol®-V Lotio 0,1%; -mite Creme 0,05% | -Creme 0,1%; -mite Salbe 0,05% | -Salbe 0,1%

Hauterkrankungen, die auf lokale Corticoidbehdlg. ansprechen.

Betnesol®-V Lotio Description, Presentation and Dosage

Betnesol®-V Lotio Description

Betnesol®-V Lotio Drug Class Description

Einzelstoffe

Betnesol®-V Lotio Drug Description

1 g enth.: Betamethason-17-valerat 1,22 mg (entspr. 1 mg Betamethason).

Betnesol®-V Lotio Generic Name

Betnesol®-V Lotio 0,1%

Betnesol®-V Lotio Presentation

Betnesol®-V Lotio Presentation

Betnesol®-V Lotio 0,1%; -mite Creme 0,05%/-Creme 0,1%; -mite Salbe 0,05%/-Salbe 0,1%

Betnesol®-V Lotio Manufacturer

Glaxo Wellcome/Cascan

Related Learning Zones

Cystic Fibrosis Knowledge Centre

Cystic Fibrosis Knowledge Centre

Cystic fibrosis (CF) is a genetic condition caused by a defect in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. The Cystic Fibrosis Knowledge Centre provides healthcare professionals with access to disease awareness information, emerging and established treatment options and current best practice based on recently updated guidelines by the European Cystic Fibrosis Society (ECFS). A resources section contains external links to upcoming medical conferences and patient support groups.

This resource is developed by EPG Health Media for epgonline.org, supported by an independent educational grant from Vertex.

Type 1 Childhood Diabetes CME

Type 1 Childhood Diabetes CME

In this EACCME-accredited online CME activity Individual Patient Management in Type 1 Childhood Diabetes, healthcare professionals will learn how to assess the psychosocial wellbeing of young patients with type 1 diabetes. 

Upon successful completion of this activity, healthcare professionals (such as endocrinologists, paediatricians, paediatric endocrinologists, diabetes specialists, specialist nurses, primary care physicians) will be awarded 1 European CME credit (ECMEC).

Betnesol®-V Lotio Dosage

Betnesol®-V Lotio Adult Dosage

Cetylstearylalkohol, Methyl-4-hydroxybenzoat, Diethylenglycolmonostearat, Cetomacrogol 1000, dickfl. Paraffin, Glycerol, Isopropylalkohol.

Betnesol®-V Lotio Child Dosage


Betnesol®-V mite Creme 0,05%/-Creme 0,1%
Zus.: 1 g enth.: Betamethason-17-valerat 0,61 mg/1,22 mg (entspr. 0,5 mg/1 mg Betamethason).
Weit. Bestandteile: Chlorocresol, Cetomacrogol 1000, Cetylstearylalkohol, weißes Vaselin, dickflüssiges Paraffin.

Betnesol®-V mite Salbe 0,05%/-Salbe 0,1%
Zus.: 1 g enth.: Betamethason-17-valerat 0,61 mg/1,22 mg (entspr. 0,5 mg/1 mg Betamethason).
Weit. Bestandteile: Dickflüssiges Paraffin, Weißes Vaselin.

Betnesol®-V Lotio Precautions, Reactions and Contraindications

Betnesol®-V Lotio Special Precautions

Betnesol®-V Lotio Special Precautions

G 12, Z 3. Anwendung am Augenlid, Akne, Pruritus anogenitalis, Virusinfektionen, Säuglinge

Related Drugs - Dermatology

Back to top